No abstract available
MeSH terms
-
Age Factors
-
Disease Progression
-
Fatal Outcome
-
Female
-
Glucan 1,4-alpha-Glucosidase / administration & dosage*
-
Glucan 1,4-alpha-Glucosidase / adverse effects*
-
Glucan 1,4-alpha-Glucosidase / deficiency
-
Glycogen / metabolism
-
Glycogen Storage Disease Type II / enzymology
-
Glycogen Storage Disease Type II / physiopathology
-
Glycogen Storage Disease Type II / therapy*
-
Humans
-
Infant, Newborn
-
Lysosomes / drug effects
-
Lysosomes / metabolism
-
Male
-
Muscle Weakness / drug therapy
-
Muscle Weakness / enzymology
-
Muscle Weakness / physiopathology
-
Respiration, Artificial / adverse effects*
-
Respiratory Insufficiency / drug therapy
-
Respiratory Insufficiency / enzymology
-
Respiratory Insufficiency / physiopathology
-
Respiratory Muscles / drug effects*
-
Respiratory Muscles / enzymology
-
Respiratory Muscles / physiopathology
-
Treatment Failure
-
Ventilator Weaning / statistics & numerical data*
Substances
-
Glycogen
-
Glucan 1,4-alpha-Glucosidase